Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2020-06-14 Regulatory Filings
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Cellmid Reports on Results of The Doherty Institute Testing 4 pages 141.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement by Cellmid Limited reporting on the results of the Doherty Institute testing of the Wondfo SARS-CoV-2 Antibody Tests. It provides detailed performance data comparing the Doherty Institute's interim report results with the manufacturer's clinical validation data. The document discusses clinical validation, testing methodologies, and implications for the use of the test. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about product testing results and validation, not a financial or governance report. The document is over 11,000 characters, so it is not a brief announcement of a report publication. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to product testing and validation results submitted to the Therapeutic Goods Administration (TGA) and the Australian Therapeutic Goods Register (ARTG).
2020-06-14 English
Reinstatement to Official Quotation 1 page 90.2KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement of trading for Cellmid Limited. It is a brief notice about the lifting of suspension on the company's securities and does not contain financial data, detailed reports, or regulatory filings beyond the announcement itself. The document length is short (707 characters), and it serves as an official notice rather than a detailed report or financial statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for general regulatory announcements that do not fit other specific categories.
2020-06-14 English
CDY signs Introducer Agreement to broaden product offering 4 pages 171.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited regarding the signing of an Introducer Agreement with Emergence Technology Pty Ltd to broaden its SARS-CoV-2 product offering. The content focuses on the details of the agreement, product descriptions, regulatory compliance, and business implications. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a business agreement and product supply arrangement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a typical corporate announcement about a new business agreement, which aligns best with the Regulatory Filings (RNS) category, which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories. The document length is substantial and contains detailed information about the agreement, but it is not a report or financial statement itself.
2020-06-03 English
Appointment of Dr Dominic Burg as Chief Operating Officer 2 pages 67.1KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Cellmid Limited dated 1 June 2020, announcing the appointment of Dr Dominic Burg as Chief Operating Officer effective 1 July 2020. The content focuses exclusively on management changes, describing Dr Burg's background, role, and quotes from the CEO and Chairman. There is no financial data, report publication, or regulatory filing referenced. The document length is 4753 characters, which is sufficient for a full announcement. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2020-05-31 English
General Meeting Presentation 19 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation discussing company operations, product lines, and COVID-19 diagnostics, including forward-looking statements and agenda items. It includes financial data such as FY2019 revenue and YTD FY2020 revenue, operational updates, and product information. The format and content are consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal regulatory filing or financial report. There is no indication that this is an official annual or interim report, audit report, or earnings release. The presence of slides, forward-looking statements, and detailed business overview aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-05-20 English
Results of Meeting 2 pages 93.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement dated 21 May 2020 from Cellmid Limited regarding the results of a General Meeting held on the same day. It details the voting outcomes on various resolutions, including approval of share issues to directors and ratification of placement shares. The text references the Corporations Act and ASX Listing Rules, and includes a summary of proxy votes and poll results. The document is concise (3816 characters) and primarily serves to communicate the official voting results of the meeting rather than the meeting materials or the meeting itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-05-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.